This analysis performed in the BEVERLY-2 phase II trial identified MMP2 and MMP9 as candidate biomarkers correlated consistently to DFS and OS in patients with HER2-positive inflammatory breast cancer. This evidence concerns the gene MMP2 and inflammatory breast carcinoma.